Ginkgolide B (Diterpene Lactone · PAF Antagonist · Anti-thrombotic · Ginkgo biloba)
| Compound | Ginkgolide B |
| Chemical class | Terpenoid — Diterpene Lactone (Cage-structured PAF antagonist; unique caged diterpenoid) |
| CAS | 15291-77-7 |
| Primary source | Ginkgo biloba (maidenhair tree, leaves and roots) |
| Key applications | Platelet-activating factor (PAF) antagonist; anti-thrombotic; neuroprotective; cognitive support |
| Claim strength | Moderate |
| Typical form | Ginkgo biloba extract standardised to 6% terpene trilactones (ginkgolides A+B+C + bilobalide) |
| Buy from Herbuno |
Ginkgo Biloba Extract Powder → Ginkgo Biloba Leaf Liquid Extract (Water Soluble) → |
Name origin: From Ginkgo (the genus) + -olide (lactone suffix). Ginkgolide B is one of four ginkgolides (A, B, C, J) unique to Ginkgo biloba — they are found nowhere else in the plant kingdom. The ginkgolide scaffold is a cage-structured diterpene lactone containing a tert-butyl group and six five-membered rings — described by Nobel laureate Elias James Corey as “the most complex natural product ever synthesised at the time” when his group accomplished the total synthesis in 1988 (33 steps). This structural complexity is one reason Ginkgo biloba extract relies entirely on botanical extraction rather than synthesis. Traditional use: Ginkgo leaf preparations have been used in Traditional Chinese Medicine for over 2,000 years — for respiratory conditions, cardiovascular support, and cognitive function. European phytomedicine adopted standardised ginkgo extract (EGb 761) in the 1960s, which became one of the best-selling botanical medicines globally. Pharmacology — PAF antagonism: Ginkgolide B is the most potent PAF (platelet-activating factor) receptor antagonist among the ginkgolides. PAF is a phospholipid mediator of platelet aggregation, bronchoconstriction, neutrophil activation, and vascular permeability. Ginkgolide B inhibits PAF binding to its G-protein coupled receptor, reducing platelet aggregation and thrombosis without directly inhibiting thromboxane or prostaglandin pathways. Commercial source: Ginkgo Biloba extract in water-soluble, oil-soluble, and dry powder forms is available from Herbuno; all co-deliver ginkgolides A, B, C alongside bilobalide and flavonol glycosides.
Evidence for Ginkgolide B Applications
Anti-thrombotic — PAF antagonism: Ginkgolide B reduces PAF-induced platelet aggregation and ADP-induced aggregation in human platelet studies. Clinical relevance in cardiovascular prevention is mechanistically supported but the specific ginkgolide B contribution to EGb 761’s clinical effects has not been isolated from the full extract pharmacology. Claim strength: Moderate.
Neuroprotection and cognitive support (as part of EGb 761): EGb 761 (standardised to 24% flavonol glycosides + 6% terpene trilactones including ginkgolide B) has demonstrated in multiple RCTs: improved cognitive function in mild cognitive impairment and early Alzheimer’s disease; reduced tinnitus severity; improved intermittent claudication. The GuidAge trial (n=2,854, 5 years) found EGb 761 did not significantly reduce dementia conversion from MCI. The IADVANCE/GINDEM trials showed cognitive benefit in Alzheimer’s patients already diagnosed. Individual ginkgolide B contribution to cognition is attributed primarily to PAF antagonism reducing cerebrovascular thrombotic events, alongside bilobalide’s direct neuroprotective effects. Claim strength: Moderate (for EGb 761 extract; ginkgolide B-specific attribution moderate).
Migraine aura — specific ginkgolide B application: A distinct clinical application: ginkgolide B (40–80 mg/day as the isolated compound in a specific Italian formulation) has been studied specifically for migraine with aura prevention — with two small Italian RCTs showing significant reduction in aura frequency. The mechanism targets cortical spreading depression (CSD) via PAF antagonism. This specific ginkgolide B formulation (not whole Ginkgo extract) is approved in Italy for migraine with aura. Claim strength: Moderate (small RCTs; specific formulation).
Ginkgo Biloba Extract Powder →
Ginkgo Biloba Leaf Liquid Extract (Water Soluble) →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Standard EGb 761 dose: 120–240 mg/day of standardised Ginkgo extract (24% flavonol glycosides, 6% terpene trilactones, <5 ppm ginkgolic acids). At 6% terpene trilactones, 120 mg extract delivers ~7.2 mg total terpene trilactones. Ginkgolides A, B, C, and bilobalide are present in approximately 3:1:1:3 ratio in most standardised extracts, giving approximately 1–2 mg ginkgolide B per standard 120 mg dose. For the specific migraine with aura Italian formulation: 40–80 mg isolated ginkgolide B — not achievable from standard extract at typical doses. Critical quality specification: ginkgolic acid content must be <5 ppm (ginkgolic acids are allergenic and have been associated with adverse reactions; the EU requires <5 ppm in supplements). Specify CoA with ginkgolic acid quantification for all Ginkgo materials.
Frequently Asked Questions — Ginkgolide B
What is the difference between ginkgolides and bilobalide in Ginkgo extract?
Ginkgolides (A, B, C, J) are diterpene lactones with the caged cage structure; their primary mechanism is PAF antagonism. Bilobalide is a different terpene trilactone (sesquiterpene) with primary neuroprotective mechanisms via GABA-A receptor modulation and mitochondrial protective effects. Both are part of the 6% terpene trilactone fraction in standardised EGb 761 extract. Bilobalide is considered to contribute more significantly to neuroprotective and cognitive effects; ginkgolides contribute more to the anti-thrombotic and anti-PAF effects.
Does Ginkgo biloba interact with blood-thinning medications?
Yes — ginkgolide B’s anti-platelet activity creates an additive risk with anticoagulants (warfarin) and antiplatelet drugs (aspirin, clopidogrel). Multiple case reports of bleeding complications exist with Ginkgo + warfarin combinations. Ginkgo supplements should be discontinued at least 14 days before surgery. The FDA has not issued a formal interaction warning but the clinical evidence supports this precaution. Formulators should include standard anticoagulant advisory language.
Did Ginkgo biloba extract prevent Alzheimer’s disease in the GuidAge trial?
The GuidAge trial (France, n=2,854, 5 years EGb 761 vs placebo in 70+ year-olds with memory complaints) found no statistically significant reduction in dementia incidence — the primary endpoint was not met. However, subgroup analyses suggested possible benefit in EGb 761 users who also took anti-hypertensives. Subsequent systematic reviews have concluded that EGb 761 may modestly slow cognitive decline in patients already diagnosed with mild-to-moderate Alzheimer’s, but does not prevent conversion from MCI to dementia in the general aging population. This represents an important evidence distinction for marketing.
Why are ginkgolic acids a quality concern in Ginkgo supplements?
Ginkgolic acids are alkylphenol compounds in ginkgo leaves (also related to the urushiol allergens of poison ivy). They cause allergic contact dermatitis, cytotoxicity in cell models, and are suspected genotoxins. Well-manufactured Ginkgo extracts remove ginkgolic acids during processing. EU regulations require <5 ppm in supplements; some market experts advocate <1 ppm. Ginkgolic acid content is not always disclosed on product labels — formulators should request specific CoA data for this contaminant from all Ginkgo extract suppliers.
Related compounds: Bilobalide, Parthenolide, Ginsenoside Rb1, Boswellic Acid
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery